       Document 0948
 DOCN  M9440948
 TI    HIV experimental vaccines based on the iscom technology using envelope
       and GAG gene products.
 DT    9404
 AU    Akerblom L; Nara P; Dunlop N; Putney S; Morein B; National Veterinary
       Institute, Department of Virology, Uppsala,; Sweden.
 SO    Biotechnol Ther. 1993;4(3-4):145-61. Unique Identifier : AIDSLINE
       MED/94122664
 AB    In previous experiments gp160 incorporated into iscom was shown to
       induce neutralizing antibodies to the homologous as well as the
       heterologous isolates of HIV-1 (Akerblom et al., AIDS Res., 1991). In
       the present work we have incorporated into iscoms three defined
       recombinant DNA products of HIV-1. The carboxy-terminal part of gp120
       expressed in E. Coli-PB-1; a chimera containing parts of both p24 and
       p15 expressed in E. coli-GAG; and baculovirus gp160 cloned in
       baculovirus and produced in insect cells. Immune responses were induced
       by the iscom preparations to the homologous antigen as well as to
       defined recombinant products and to the synthetic peptide RP135 (aa
       304-328) harboring a neutralizing epitope. Sera from mice immunized with
       PB1-iscoms and gp160 (baculo) iscoms were tested in a syncytie
       inhibition assay. The serum from a mouse immunized with PB1 iscoms
       reacted strongly with the synthetic peptide RP135 and also neutralized
       the homologous isolate HIV-1/IIIB with a neutralization titer of 1/64.
       Three gp160 (baculo) iscom antisera were tested, of which two reacted
       strongly with the synthetic peptide RP135 but did not neutralize the
       homologous isolate HIV-1/IIIB. High serum titers were induced in mice by
       the gp160 iscoms (2 micrograms) to homologous antigen and the
       recombinant DNA E. coli construct p121 covering part of gp41. The
       ceilings of the antibody responses were reached after two immunizations.
       The PB1- and GAG-iscoms required three immunizations to reach the
       ceiling of the antibody response.
 DE    Animal  AIDS Vaccines/*IMMUNOLOGY  Blotting, Western  Enzyme-Linked
       Immunosorbent Assay  Escherichia coli/GENETICS  Gene Products,
       env/*IMMUNOLOGY  Gene Products, gag/*IMMUNOLOGY  HIV
       Antibodies/*BIOSYNTHESIS  HIV Core Protein p24/IMMUNOLOGY  HIV Envelope
       Protein gp120/IMMUNOLOGY  ISCOMs/*IMMUNOLOGY  Mice  Mice, Inbred BALB C
       Protein Precursors/IMMUNOLOGY  Recombinant Proteins/IMMUNOLOGY  Support,
       Non-U.S. Gov't  Vaccination  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

